Haixi Pharmaceuticals Advances Oral nAMD Drug HX9428 With U.S. FDA Nod and New China TrialTip Ranks·1 day ago, 04:38 AM02637+0.50%
Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trialPUBT·1 day ago, 04:13 AM02637+0.50%REGN+1.04%
Fujian Haixi Pharma shareholders approved external auditor change at EGMPUBT·1 day ago, 03:55 AM02637+0.50%
Fujian Haixi Pharmaceuticals files board, board committee member list with disclosure rolesPUBT·1 day ago, 03:55 AM02637+0.50%
Fujian Haixi Pharma discloses RMB 577.22 million investments equal to 31.3% of 2025 total assetsPUBT·2 days ago, 03:33 AM02637+0.50%
From GLP-1 Hype to Tokenization Mirages: Hong Kong's Fringe Market is a Wild RideGlobal Report·Jul 28 at 04:12 AM02591-2.04%02637+0.50%
Fujian Haixi Pharma Calls 2026 EGM to Approve Auditor Change and New DirectorTip Ranks·Jul 15 at 06:08 AM02637+0.50%
Fujian Haixi Pharmaceuticals plans auditor switch to RSM China from DeloittePUBT·Jul 15 at 05:33 AM02637+0.50%
Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trialPUBT·Jul 14 at 04:08 AM02637+0.50%
Haixi Pharmaceuticals Launches Phase III Trial for Novel Osteosarcoma DrugTip Ranks·Jul 9 at 04:11 AM02637+0.50%
